MET signaling pathway: A rational target for cancer therapy

Journal of Clinical Oncology

Volumn 29, Issue 36, 2011, Pages 4837-4838

  Appleman, Leonard J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GAMMA UROGASTRONE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 ASSOCIATED BINDING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TYROSINE; UNCLASSIFIED DRUG;

ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL COMMUNICATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CYTOPLASM; DRUG TARGETING; ENZYME ACTIVATION; EPITHELIUM CELL; ESOPHAGUS CARCINOMA; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MESENCHYME CELL; METASTASIS; MORPHOGENESIS; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84555202728     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.7929     Document Type: Article

References (14)

1. Graziano F, Galluccio N, Lorenzini P, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789-4795, 2011
2. Lennerz JK, Kwak EL, Ackerman A, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810, 2011
3. Boccaccio C, Comoglio PM: Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645, 2006 (Pubitemid 44140861)
4. Trusolino L, Bertotti A, Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834-848, 2010
5. Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29- 33, 1984
6. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997 (Pubitemid 27198158)
7. Yap TA, Olmos D, Brunetto AT, et al: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271-1279, 2011
8. Gordon MS, Sweeney CS, Mendelson DS, et al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-inhuman study of patients with advanced solid tumors. Clin Cancer Res 16:699-710, 2010
9. Gordon MS, Vogelzang NJ, Schoffski P, et al: Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 29:196s, 2011 (suppl; abstr 3010)
10. Qi J, McTigue MA, Rogers A, et al: Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71:1081-1091, 2011
11. Cepero V, Sierra JR, Corso S, et al: MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70:7580-7590, 2010
12. Danilkovitch-Miagkova A, Zbar B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109:863-867, 2002 (Pubitemid 34275106)
13. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
14. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007 (Pubitemid 46799492)